The latest price target for Halozyme Therapeutics (NASDAQ:HALO) was reported by Wells Fargo on January 13, 2025. The analyst firm set a price target for $57.00 expecting HALO to fall to within 12 months (a possible -3.49% downside). 41 analyst firms have reported ratings in the last year.

The latest analyst rating for Halozyme Therapeutics (NASDAQ:HALO) was provided by Wells Fargo, and Halozyme Therapeutics maintained their equal-weight rating.

The last upgrade for Halozyme Therapeutics Inc happened on May 10, 2023 when Piper Sandler raised their price target to $46. Piper Sandler previously had a neutral for Halozyme Therapeutics Inc.

The last downgrade for Halozyme Therapeutics Inc happened on October 7, 2024 when Wells Fargo changed their price target from $58 to $62 for Halozyme Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.

While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a maintained with a price target of $62.00 to $57.00. The current price Halozyme Therapeutics (HALO) is trading at is $59.06, which is out of the analyst’s predicted range.